Published September 29, 2025 01:53 PM EDT Morgan Stanley analysts have downgraded Novo Nordisk's stock, pointing in part to falling sales of weight-loss drugs Ozempic and Wegovy. Steve Christo - Corbis / Corbis via Getty Images Key Takeaways An analyst's concerns about demand for Novo Nordisk's blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week. U.S.-listed shares of Novo Nordisk (NVO) slid in recent trading following a downgrade from Morgan Stanley, which raised concerns ...